The purpose of this research is to see if the DPP4 inhibitor linagliptin, an oral medication commonly used to treat type 2 diabetes,can help with diabetes control and reduce the severity of the COVID-19 infection
Drug: Linagliptin
5 mg Linagliptin administered by mouth once daily
Other Name: Tradjenta
Drug: Insulin regimen
Standard of care insulin regimen as per hospital protocol
Inclusion Criteria: - Type 2 Diabetes Mellitus (T2DM) as per American Diabetes Association (ADA) guidelines - Age ≥ 18 - Confirmed COVID-19 - Mild COVID-19 defined as any of the following: fever, malaise, cough, headache, sore throat, myalgia, nasal congestion, diarrhea - Moderate COVID-19 is defined as > 2 of the following in non-intubated patients: any symptom of mild disease, radiographic imaging (chest x-ray or lung ultrasound) with bilateral ground glass opacities or bilateral consolidations, SpO2
University of Miami
Miami, Florida, 33136
Gianluca Iacobellis, MD PhD
3052433636
giacobellis@med.miami.edu
Gianluca Iacobellis, MD PhD
Principal Investigator
University of Miami